Detail of "7059-24-7"

Reference

Chromomycin, olivomycin, and bleomycin as inhibitors of DNA and RNA polymerases

Chromomycin, olivomycin, and bleomycin as inhibitors of DNA and RNA polymerases. Mueller, Werner E. G. (Inst. Physiol. Chem., Univ. Mainz, Mainz, Ger.). Pharmacol. Ther., Part A, 1(4), 457-74 (English) 1977. CODEN: PTPAD4. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacodynamics) Section cross-reference(s): 7 A review with 77 refs. on bleomycin [11056-06-7], chromomycin [7059-24-7], and olivomycin [6988-58-5] as inhibitors of DNA polymerase [9012-90-2] and RNA polymerase [9014-24-8].

Combination chemotherapy for solid tumors using 5-fluorouracil, chromomycin-A3, and prednisolone

Combination chemotherapy for solid tumors using 5-fluorouracil, chromomycin-A3, and prednisolone. Saito, Tatuo; Wakui, Akira; Yokoyama, Masakazu; Himori, Tatsumi; Takahashi, Hiromu; Kudo, Toshio; Takahashi, Kenichi (Res. Inst. Tuberc., Leprosy Cancer, Tohoku Univ., Sendai, Japan). Gann, 68(4), 375-87 (English) 1977. CODEN: GANNA2. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacodynamics) Section cross-reference(s): 2 The clin. effect of 5-fluorouracil [51-21-8] or chromomycin A3 [7059-24-7] alone, 5-fluorouracil plus chromomycin A3, and of the 1st two plus prednisolone [50-24-8] on gastrointestinal and other solid tumors was evaluated. Of 133 cases acceptable for evaluation, the no. of responders was as follows: 3 (18.8%) of 16 cases treated with 5-fluorouracil alone, 1 (9.1%) of 11 cases treated with chromomycin A3 or chromomycin A3 hemisuccinate [23276-33-7], 13 (21.7%) of 60 cases on the 2-drug regimen, and 21 (45.7%) of 46 cases on the 3-drug regimen. In cases of stomach carcinoma, response rate to the 3-drug regimen was 54.2% (13/24), significantly higher than that with other regimens. At least 25% regression in the size of primary tumor was obsd. in 2 (7.1%) of 28 cases on the 2-drug regimen and in 6 (33.3%) of 18 cases on the 3-drug regimen. Of 51 cases on the 3-drug regimen, steroid diabetes developed in 5 cases, moon face in 4 cases, and gastric ucler in 1 case. However, the toxic effect of these regimens (esp. appearance of leukopenia) was less than those of previously tried combined regimens. The av. duration of response was 10.8 weeks in 13 cases on the 2-drug regimen and 11.7 weeks in 21 cases on the 3-drug regimen. Thus, a better response is given by the 3-drug regimen than other regimens, and in addn., prednisolone in combination, in addn. to its favorable effect in improving the general condition of the patients, might enhance the anticancer effect of the drugs used in combination.